1. Impact of EPclin on adjuvant therapeutic decision making and comparison of EPclin to the PREDICT tool
- Author
-
Jérôme Blanchot, Vincent Lavoué, Angélique Brunot, Sophie Guillermet, Héloïse Bourien, Florence Godey, Thibault De La Motte Rouge, C. Lefeuvre-Plesse, Laurence Crouzet, Véronique Quillien, Boris Campillo-Gimenez, Véronique Diéras, Fanny Le Du, and Christophe Perrin
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Clinical Biochemistry ,Decision Making ,Pathology and Forensic Medicine ,Young Adult ,Breast cancer ,Internal medicine ,medicine ,Humans ,In patient ,Prospective Studies ,Aged ,Retrospective Studies ,Chemotherapy ,Framingham Risk Score ,business.industry ,Cancer ,Therapeutic decision making ,Middle Aged ,medicine.disease ,Prognosis ,Chemotherapy, Adjuvant ,Female ,business ,Adjuvant - Abstract
Purpose: Genomic signatures, such as EndoPredict®, may help clinicians to decide which adjuvant treatment is the most appropriate. Methods: We propose the EndoPredict® assay for unclear cases of adjuvant treatment in patients treated in our comprehensive cancer center. We prospectively and retrospectively report the decision of adjuvant treatment before and after the EndoPredict® assay, respectively, compared to the PREDICT’s tool scores. Results: From November 2016 to March 2019, 159 breast cancer tumors were analyzed and presented before and after the EndoPredict® assay. Before the EndoPredict® results, clinicians recommended chemotherapy for 57 patients (57/159, 36%). A total of 108 patients (108/159, 68%) were classified as EPclin high-risk score. There was only a slight agreement between clinicians’ decisions and EPclin risk score. The EPclin score led to 37% changes in treatment (59/159); chemotherapy was favored in 80% of cases (47/59). The PREDICT tool recommended chemotherapy for 16 high-risk patients (16/159, 10%). Conclusion: Although genomic tests were developed in order to de-escalate adjuvant treatment, in our comprehensive cancer center the use of the EndoPredict® assay led to an increase in prescribed chemotherapy.
- Published
- 2021